1. Left ventricular electrical delay predicts volumetric response to leadless cardiac resynchronization therapy.
- Author
-
Wijesuriya N, Mehta V, De Vere F, Howell S, Mannakkara N, Sidhu B, Elliott M, Bosco P, Sanders P, Singh JP, Walsh MN, Niederer SA, and Rinaldi CA
- Abstract
Background: Leadless left ventricular (LV) endocardial pacing is an emerging cardiac resynchronization therapy (CRT) technology. Predictors of response to leadless CRT are poorly understood. Implanting the LV endocardial pacing electrode in sites with increased electrical latency (Q-LV) may improve response rates., Objective: The purpose of this study was to examine the association between Q-LV and echocardiographic remodeling response to leadless CRT delivered with the WiSE-CRT system., Methods: A post hoc analysis (n = 122) of the SOLVE-CRT trial examined the relationship between LV pacing site Q-LV with rate of left ventricular end-systolic volume (LVESV) reduction >15% at 6 months. Multivariable regression analysis, adjusting for age, sex, previous CRT nonresponse, cardiomyopathy etiology, QRS morphology, and QRS duration was performed, followed by receiver operating characteristic analysis and analysis of variance by Q-LV quartile. A subgroup analysis of the ischemic cardiomyopathy cohort was undertaken., Results: Complete Q-LV data were available for 122 of 153 patients (80%) in the active arms SOLVE-CRT. Overall, the 6-month LVESV response rate was 46%. Logistic regression identified Q-LV as an independent response predictor with borderline significance (adjusted odds ratio 1.015; P = .05). Analysis by Q-LV quartile demonstrated a significant improvement in response rate in quartile 4 (longest Q-LV 64%) compared to quartile 1 (shortest Q-LV 28%) (P <.01). This association was primarily driven by strong Q-LV-response correlation in patients with ischemic cardiomyopathy, demonstrated by subgroup logistic regression (adjusted odds ratio 1.034; P = .004)., Conclusion: Increased Q-LV was associated with improved reverse remodeling following leadless CRT. Targeting LV endocardial sites of high Q-LV may deliver additional benefit compared to empirical LV electrode implantation., Competing Interests: Disclosures Dr Sanders has served on the advisory board of Medtronic, Abbott, Boston-Scientific, Pacemate, and CathRx; reports that the University of Adelaide has received on his behalf lecture and/or consulting fees from Medtronic, Boston Scientific, and Abbott; and reports that the University of Adelaide has received on his behalf research funding from Medtronic, Abbott, Boston Scientific, and Microport CRM. Dr Singh has received consulting fees from Abbott, Boston Scientific, Biotronik, Biosense Webster, Cardiologs Inc, CVRx Inc, EBR Systems, Implicity Inc, Impulse Dynamics, Rhythm Management Group, Medtronic, Sanofi, and WebMD; has received honoraria from Abbott, Boston Scientific, Biotronik, Biosense Webster, CVRx Inc, Impulse Dynamics, Medtronic, Sanofi, and WebMD; and has served on the Board of Trustees of the Heart Rhythm Society (unpaid). Dr Rinaldi receives research funding and/or consultation fees from Abbott, Medtronic, Boston Scientific, Spectranetics, EBR Systems, and MicroPort. All other authors have no conflicts of interest to disclose., (Copyright © 2024 Heart Rhythm Society. Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF